Cost-Effectiveness of Nivolumab Plus Ipilimumab versus Chemotherapy for Previously Untreated Metastatic NSCLC Using Mixture-Cure Survival Analysis Based on CheckMate 227 5-Year Data
This study suggests NIVO+IPI may be a cost-effective first-line treatment when compared with chemo in a US setting given a threshold of US$150,000 per QALY. The cost-effectiveness analysis used a mixture-cure approach, which may offer a more appropriate modelling method in immuno-oncology given LTR, by more accurately capturing the potential treatment benefit.
Authors
- Mohammad A. Chaudhary (ORCID: https://orcid.org/0000-0001-6552-9093)
- Yong Yuan (ORCID: https://orcid.org/0000-0001-9720-1965)
- Jason Gordon (ORCID: https://orcid.org/0000-0001-8635-742X)
- Robert D. Young (ORCID: https://orcid.org/0000-0001-7432-9165)
- Adam Lee (ORCID: https://orcid.org/0000-0001-8834-1296)
- Alison Griffiths (ORCID: https://orcid.org/0000-0002-4324-1256)
- Philip McEwan
Institutions
- Bristol-Myers Squibb (United States) (US)
- Bristol-Myers Squibb (United Kingdom) (GB)
- Health Economics and Outcomes Research (United Kingdom) (GB)
Publication Details
- Journal
- PharmacoEconomics - Open
- Published
- 2024-12-06
- DOI
- https://doi.org/10.1007/s41669-024-00545-z
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- Bristol-Myers Squibb